NMDA antagonists
Articles tagged with “NMDA antagonists”
AXS-05 Nears FDA Decision for Alzheimer's Agitation
AXS-05, an oral NMDA-targeting drug, nears FDA approval for Alzheimer's agitation. Here's what it means for the ketamine treatment landscape.
Side Effects & Dropout Rates: New Data on Ketamine for TRD
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insight for patients considering ketamine therapy for TRD.
Why Patients Quit NMDA Therapy—And What Providers Should Do
New clinical review urges faster dose optimization and earlier switching between NMDA therapies for treatment-resistant depression. Here's what it means for patients.
NMDA Side Effects: What Dropout Rates Mean for Patients
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insights for patients considering ketamine or esketamine therapy.
Ketamine Side Effects: What New Clinical Data Reveals
New clinical analysis examines side effect profiles and discontinuation rates for ketamine and esketamine. Here's what treatment-resistant depression patients should know.
Ketamine Side Effects: What New Data Tells Patients
A new clinical review examines side effect profiles and discontinuation rates for NMDA antagonists like ketamine and esketamine. Here's what patients should know.
Ketamine Side Effects: What New Data Means for Patients
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives patients and families sharper questions to ask before starting ketamine therapy.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.